Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT ID: NCT03877510

Last Updated: 2023-07-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

419 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-03

Study Completion Date

2022-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 9-month, multicenter open-label safety extension study. Participants who have successfully completed Study NCT03670953 \[A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in Parkinson's Disease Patients with Motor Fluctuations\] may have the opportunity to enroll in this open-label study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label IPX203

All participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety.

Group Type EXPERIMENTAL

IPX203

Intervention Type DRUG

IPX203 extended release capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IPX203

IPX203 extended release capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Successfully completed Study IPX203-B16-02
* Able to provide written informed consent prior to the conduct of any study-specific procedures.
* Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit (Visit 1).
* Agrees to use a medically acceptable method of contraception throughout the study and for 6 weeks after completing the study.

Exclusion Criteria

* Intends to use any doses of Rytary® or Duopa™ during this study.
* Plans to use an investigational treatment other than IPX203 during the course of this study.
* Neurosurgical ablation treatment for PD is planned or anticipated during the study period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study.
* Participants who, in the opinion of the clinical investigator, should not participate in the study.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Impax Laboratories, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Impax Impax Study Director

Role: STUDY_DIRECTOR

Impax Laboratories, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xenoscience, Inc (102)

Phoenix, Arizona, United States

Site Status

St. Joseph's Hospital & Medical Center - Barrow Neurological Institute (156)

Phoenix, Arizona, United States

Site Status

Clinical Trials, Inc (113)

Little Rock, Arkansas, United States

Site Status

University of Arkansas for Medical Sciences (117)

Little Rock, Arkansas, United States

Site Status

Keek School of Medicine of USC/ University of Southern California (106)

Los Angeles, California, United States

Site Status

Hoag Memorial Hospital Presbyterian (134)

Newport Beach, California, United States

Site Status

SC3 Research-Pasadena (148)

Pasadena, California, United States

Site Status

SC3 Research-Reseda (146)

Reseda, California, United States

Site Status

University of Colorado Hospital Anschutz Outpatient Pavilion (120)

Aurora, Colorado, United States

Site Status

Rocky Mountain Movement Disorders (116)

Englewood, Colorado, United States

Site Status

ChristianaCare Neurology Specialists (153)

Newark, Delaware, United States

Site Status

JEM Research Institute (136)

Atlantis, Florida, United States

Site Status

Visionary Investigators Network (168)

Aventura, Florida, United States

Site Status

UHealth at Boca Raton (152)

Boca Raton, Florida, United States

Site Status

Parkinson's Disease and Movement Disorders Center of Boca Raton (121)

Boca Raton, Florida, United States

Site Status

Infinity Clinical Research LLC (104)

Hollywood, Florida, United States

Site Status

University of Florida Health Science Center (129)

Jacksonville, Florida, United States

Site Status

Neurology Associates, P.A. (125)

Maitland, Florida, United States

Site Status

University of Miami (149)

Miami, Florida, United States

Site Status

Medical Professional Clinical Research Center, Inc. (163)

Miami, Florida, United States

Site Status

Parkinson's Disease Treatment Center of Southwest Florida (131)

Port Charlotte, Florida, United States

Site Status

Infinity Clinical Research, LLC (105)

Sunrise, Florida, United States

Site Status

University of South Florida (114)

Tampa, Florida, United States

Site Status

Premiere Research Institute at Palm Beach Neurology (174)

West Palm Beach, Florida, United States

Site Status

Charter Research (166)

Winter Park, Florida, United States

Site Status

Emory Brain Health Center (110)

Atlanta, Georgia, United States

Site Status

NeuroStudies.net, LLC (155)

Decatur, Georgia, United States

Site Status

Northwestern Medical Group Neurology Clinic (145)

Chicago, Illinois, United States

Site Status

Central DuPage Hospital (151)

Winfield, Illinois, United States

Site Status

Indiana University Health Neuroscience Center(164)

Indianapolis, Indiana, United States

Site Status

University of Kansas Medical Center (118)

Kansas City, Kansas, United States

Site Status

Quest Research Institute (103)

Farmington Hills, Michigan, United States

Site Status

Henry Ford West Bloomfield Hospital(100)

West Bloomfield, Michigan, United States

Site Status

Washington University (109)

St Louis, Missouri, United States

Site Status

Roseman Medical Research Institute / Roseman Medical Group (154)

Las Vegas, Nevada, United States

Site Status

Cleveland Clinic Lou Ruvo Center for Brain Health (142)

Las Vegas, Nevada, United States

Site Status

Albany Medical College (139)

Albany, New York, United States

Site Status

Ucgni (133)

Cincinnati, Ohio, United States

Site Status

University Hospitals Cleveland Medical Center (123)

Cleveland, Ohio, United States

Site Status

Cleveland Clinic(144)

Cleveland, Ohio, United States

Site Status

University of Toledo, Gardner-McMaster Parkinson Center (122)

Toledo, Ohio, United States

Site Status

The Movement Disorder Clinic of Oklahoma (115)

Tulsa, Oklahoma, United States

Site Status

The Vanderbilt Clinic (158)

Nashville, Tennessee, United States

Site Status

Neurology Consultants of Dallas, PA (108)

Dallas, Texas, United States

Site Status

University of Texas Southwestern Medical Center (143)

Dallas, Texas, United States

Site Status

Houston Methodist Neurological Institute/Movement Disorders Clinic (135)

Houston, Texas, United States

Site Status

Inova Neurology- Fairfax (147)

Fairfax, Virginia, United States

Site Status

VCU Health- Neuroscience Orthopaedic and Wellness Center(124)

Henrico, Virginia, United States

Site Status

Booth Gardner Parkinson's Care Center (112)

Kirkland, Washington, United States

Site Status

Inland Northwest Research (119)

Spokane, Washington, United States

Site Status

Fakultni nemocnice u sv. Anny v Brne, I. neurologicka klinika (704)

Brno, , Czechia

Site Status

NEUROHK. s.r.o. (701)

Choceň, , Czechia

Site Status

Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Neurologicka klinika (702)

Pardubice, , Czechia

Site Status

CLINTRIAL s.r.o. (703)

Prague, , Czechia

Site Status

AXON Clinical. s.r.o. (700)

Prague, , Czechia

Site Status

Neurologicka ordinace FORBELI s.r.o. (706)

Prague, , Czechia

Site Status

CHU de Clermont-Ferrand-Hopital Gabriel Montpied (404)

Clermont-Ferrand, , France

Site Status

CHU de Montpellier, Hopital Gui de Chauliac (405)

Montpellier, , France

Site Status

Centre Hospitalier Universitaire de Nice (400)

Nice, , France

Site Status

Centre d'lnvestigation Clinique 1436- CHU Purpan- Hopital Pierre Paul Riquet (403)

Toulouse, , France

Site Status

Kliniken Beelitz GmbH, neurologisches Fachkrankenhaus fur Bewegungsstorungen/Parkinson (300)

Beelitz-Heilstätten, Beelitz, Germany

Site Status

St. Josef-Hospital, Universitatsklinik fur Neurologie Klinisches Forschungszentrum fur Neurodegeneration (301)

Bochum, Gudrunstabe 56, Germany

Site Status

Klinikum rechts der lsar der Technischen Universitat Munchen Klinik und Poliklinik fur Neurologie (303)

München, Ismaningerstrabe, Germany

Site Status

Dr. med. Reinhardt Ehret Neuroloqie Berlin Schlobstr. 29 (309)

Berlin, , Germany

Site Status

Klinik Haag i. OB Geriatric Hospital Krankenhausstrabe 4 (305)

Haag in Oberbayern, , Germany

Site Status

Gemeinschaftspraxis Dr. med. J. Springub/W. Schwarz, Studienzentrum Nordwest (306)

Westerstede, , Germany

Site Status

Centro Ricerca Parkinson San Raffaele Cassino (601)

Cassino, Frosinone, Italy

Site Status

Università G. D'annunzio CeSi Met (604)

Chieti, Italy/Chieti/Abbruzzo, Italy

Site Status

Fondazione I st ituto Neurologico Nazionale "C. Mondino" (606)

Pavia, Italy/Pavia/Lombardia, Italy

Site Status

Azienda Ospedaliero-Universitaria Pisana (602)

Pisa, Italy/Pisa/Toscana, Italy

Site Status

IRCCS San Raffaele Pi sana (600)

Roma, Italy/Roma/Lazio, Italy

Site Status

Department of neuroscience, mental health and sensory system (NeSMOS), "Sapienza" University (603)

Roma, Italy/Roma/Lazio, Italy

Site Status

University of Rome Tor Vergata/Hospital Tor Vergata (605)

Rome, Lazio, Italy

Site Status

Department "G. F. Ingrassia" section of neuroscience - Policlinico "Vittorio Emanuele" (608)

Catania, Sicily, Italy

Site Status

Centrum Medyczne Neuromed (803)

Bydgoszcz, , Poland

Site Status

Centrum Medyczne Linden (805)

Krakow, , Poland

Site Status

Krakowska Akademia Neurologii Sp. Zo.o.(802)

Krakow, , Poland

Site Status

NZOZ Neuromed M. i M. Nastaj Sp.p. (800)

Lublin, , Poland

Site Status

NZOZ Neuro-Kard Ilkowski i Partnerzy Spolka Partnerska Lekarzy (801)

Poznan, , Poland

Site Status

Neuro-Care Sp. z o.o. sp. k. (804)

Siemianowice Śląskie, , Poland

Site Status

Centrum Medycme NeuroProtect (806)

Warsaw, , Poland

Site Status

Hospital General Universitario de Elche (509)

Elche, Alicante, Spain

Site Status

Hospital Universitari General de Catalunya (504)

Sant Cugat del Vallès, Barcelona, Spain

Site Status

Hospital Universitari Mutua Terrassa (506)

Terrassa, Barcelona, Spain

Site Status

Policlinica Gipuzkoa, S.A (511)

Donostia / San Sebastian, Gipuzkoa, Spain

Site Status

Clinica Universidad de Navarra (512)

Pamplona, Navarre, Spain

Site Status

Hospital Universitario Quiron Dexeus (501)

Barcelona, , Spain

Site Status

Germanes Hospitalaries Del Sagrat Cor De Jesus Hospital Sant Rafael (516)

Barcelona, , Spain

Site Status

Hospital Universitario Vall d'Hebron (505)

Barcelona, , Spain

Site Status

Hospital de Ia Santa Creu i Sant Pau (502)

Barcelona, , Spain

Site Status

Hospital Universitario de Ia Princesa (508)

Madrid, , Spain

Site Status

Hospital Universitario Ramon y Cajal (500)

Madrid, , Spain

Site Status

Hospital Universitario Infanta Sofia(513)

Madrid, , Spain

Site Status

Hospital Universitario Virgen del Rocio (503)

Seville, , Spain

Site Status

Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell (515)

Valencia, , Spain

Site Status

Re:Cognition Health Ltd (205)

Plymouth, Devon, United Kingdom

Site Status

Imperial College Healthcare NI-lS Trust (200)

London, , United Kingdom

Site Status

Re:Cognition Health Ltd (202)

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Czechia France Germany Italy Poland Spain United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-002234-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IPX203-B16-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Infusion of Apomorphine: Long-term Safety Study
NCT02339064 ACTIVE_NOT_RECRUITING PHASE3